<DOC>
	<DOC>NCT02201030</DOC>
	<brief_summary>This study will assess the immunogenicity and safety of primary vaccination with NBP606 compared to the existing commercial vaccine, when given concomitantly with routine pediatric vaccinations.</brief_summary>
	<brief_title>Immunogenicity and Safety Study of NBP606 in Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy Infants between 42 and 98 days of age (approximately 2 months) at the time of enrollment. The LAR (Legally Authorized Representative) who understand the requirements of the study and voluntarily consent to participate in the study. Known hypersensitivity to any components of the pneumococcal vaccine Any confirmed or suspected immunosuppressive or immunodeficient conditions Coagulation disorder contraindicating IM(intramuscular) vaccination Subject has received any licensed vaccine(not including BCG and Hepatitis B) Participation to another study</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>98 Days</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>